BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Nuvilex Pancreatic Cancer Trials Could Make "Cell-in-a-Box" Gold Standard


4/30/2013 11:27:01 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEW YORK, NY--(Marketwired - April 29, 2013) - While many biotech and pharmaceutical companies are designing one drug after another to address specific health problems, Nuvilex, Inc. (OTCQB: NVLX) is using its own living cell encapsulation as a "one size fits all" type solution. The company is off to a great start at getting its "Cell-in-a-Box" technology on the map with its work in late stage, inoperable pancreatic cancer.

Nuvilex is headquartered in Silver Spring, Maryland, and while it is a small international biotech, the company has been delivering big results, and now it's preparing for an even bigger stage -- Phase III clinical trials. When it comes to pancreatic cancer, you can bet the NYSE's Eli Lilly and NASDAQ's Celgene Corp. are all too familiar with Nuvilex and its technology. Currently, Eli Lilly's drug Gemzar is the only drug to date approved by the FDA as a single agent for the treatment of advanced, inoperable pancreatic cancer and the drug is considered the "gold standard" by the market. Eli Lilly introduced gemcitabine (Gemzar) back in 1996, and since that time, it has netted the drug's maker billions of dollars in sales.

Nipping at Eli Lilly's heels are both Celgene and Nuvilex, but of the three, the smallest of them all, has produced the best results in clinical trials using its living cell encapsulation. Nuvilex's "Cell-in-a-Box" is a process that forms a "platform" upon which treatments for many serious, debilitating, and even fatal diseases may be built. Some of these diseases include different types of cancer, diabetes, diseases for which stem cell therapies are being developed, and diseases caused by viruses.

The process uses living cells, and Nuvilex takes a very specific type of cell to address a specific problem a patient suffers from. Scientists then wrap up cells in a type of cellulose, forming essentially "cotton" capsules with live cells inside that form this "platform" or bundled miniature "house" of cells about the size of the head of a pin.

Continue reading this article at www.stockhousegroup.com/features

About Stock House Group

Stock House Group is a full service Investment Relations firm specializing in Awareness, Research, and Content Development. We offer a platform to CEOs to develop their story through articles, Research Reports, and CEO Interviews. Additionally, we're building a library for Investors to research small and large cap stocks.


Contact:
Stock House Group
www.stockhousegroup.com
Email Contact
646-397-4020

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

Nuvilex
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES